Literature DB >> 20040368

Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice.

R A Mans1, N Chowdhury, D Cao, L L McMahon, L Li.   

Abstract

Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, and they are widely used to control plasma cholesterol levels and prevent cardiovascular disease. However, emerging evidence indicates that the beneficial effects of statins extend to the CNS. Statins have been shown to improve the outcome of stroke and traumatic brain injury, and statin use has been associated with a reduced prevalence of Alzheimer's disease (AD) and dementia. However, prospective studies with statins in AD have produced mixed results. Recently, we reported that simvastatin, a widely used statin in humans, enhances learning and memory in non-transgenic mice as well as in transgenic mice with AD-like pathology on a mixed genetic background. However, the cellular and molecular mechanisms underlying the beneficial effects of simvastatin on learning and memory remain elusive. The present study was undertaken to investigate the effect of acute simvastatin treatment on hippocampal long-term potentiation (LTP), a cellular model of learning and memory, in brain slices from C57BL/6 mice. Our results demonstrate that a prolonged in vitro simvastatin treatment for 2-4 h, but not a short-term 20-min exposure, significantly increases the magnitude of LTP at CA3-CA1 synapses without altering basal synaptic transmission or the paired-pulse facilitation ratio in hippocampal slices. Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. These findings suggest activation of Akt as a molecular pathway for augmented hippocampal LTP by simvastatin treatment, and implicate enhancement of hippocampal LTP as a potential cellular mechanism underlying the beneficial effects of simvastatin on cognitive function. Copyright (c) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040368      PMCID: PMC2824052          DOI: 10.1016/j.neuroscience.2009.12.062

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  48 in total

1.  The discovery and development of HMG-CoA reductase inhibitors. 1992.

Authors:  Akira Endo
Journal:  Atheroscler Suppl       Date:  2004-10       Impact factor: 3.235

2.  Estrogen-induced increase in the magnitude of long-term potentiation occurs only when the ratio of NMDA transmission to AMPA transmission is increased.

Authors:  Caroline C Smith; Lori L McMahon
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

3.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

Authors:  D Larry Sparks; Marwan N Sabbagh; Donald J Connor; Jean Lopez; Lenore J Launer; Patrick Browne; Dawn Wasser; Sherry Johnson-Traver; Jeff Lochhead; Chuck Ziolwolski
Journal:  Arch Neurol       Date:  2005-05

4.  Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.

Authors:  Kina Höglund; Steinar Syversen; Piotr Lewczuk; Anders Wallin; Jens Wiltfang; Kaj Blennow
Journal:  Exp Brain Res       Date:  2005-06-04       Impact factor: 1.972

5.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice.

Authors:  Tiina J Kotti; Denise M O Ramirez; Brad E Pfeiffer; Kimberly M Huber; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 6.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

7.  Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.

Authors:  Alberto C S Costa; Michael J Grybko
Journal:  Neurosci Lett       Date:  2005-04-12       Impact factor: 3.046

8.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

Authors:  Andrew Cordle; Gary Landreth
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

9.  Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones.

Authors:  Julian Bösel; Florin Gandor; Christoph Harms; Michael Synowitz; Ulrike Harms; Pierre Chryso Djoufack; Dirk Megow; Ulrich Dirnagl; Heide Hörtnagl; Klaus B Fink; Matthias Endres
Journal:  J Neurochem       Date:  2005-03       Impact factor: 5.372

10.  Role of AMPA receptor desensitization and the side effects of a DMSO vehicle on reticulospinal EPSPs and locomotor activity.

Authors:  Nataliya A Tsvyetlynska; Russell H Hill; Sten Grillner
Journal:  J Neurophysiol       Date:  2005-08-17       Impact factor: 2.714

View more
  23 in total

1.  Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.

Authors:  Marc-Alexander L T Parent; David A Hottman; Shaowu Cheng; Wei Zhang; Lori L McMahon; Li-Lian Yuan; Ling Li
Journal:  Cell Mol Neurobiol       Date:  2014-04-01       Impact factor: 5.046

Review 2.  Protein prenylation and synaptic plasticity: implications for Alzheimer's disease.

Authors:  David A Hottman; Ling Li
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

3.  An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult rats.

Authors:  Robert Alan Mans; Brian A Warmus; Caroline C Smith; Lori L McMahon
Journal:  J Neurophysiol       Date:  2014-08-20       Impact factor: 2.714

4.  Cholesterol loss during glutamate-mediated excitotoxicity.

Authors:  Alejandro O Sodero; Joris Vriens; Debapriya Ghosh; David Stegner; Anna Brachet; Marta Pallotto; Marco Sassoè-Pognetto; Jos F Brouwers; J Bernd Helms; Bernhard Nieswandt; Thomas Voets; Carlos G Dotti
Journal:  EMBO J       Date:  2012-02-17       Impact factor: 11.598

5.  Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.

Authors:  R A Mans; L L McMahon; L Li
Journal:  Neuroscience       Date:  2011-12-13       Impact factor: 3.590

6.  The flavonoid baicalein promotes NMDA receptor-dependent long-term potentiation and enhances memory.

Authors:  Wei Wang; Fang Wang; Yuan-Jian Yang; Zhuang-Li Hu; Li-Hong Long; Hui Fu; Na Xie; Jian-Guo Chen
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 7.  Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.

Authors:  Ling Li; Wei Zhang; Shaowu Cheng; Dongfeng Cao; Marc Parent
Journal:  Mol Neurobiol       Date:  2012-03-15       Impact factor: 5.590

8.  Simvastatin Enhances Spatial Memory and Long-Term Potentiation in Hippocampal CA1 via Upregulation of α7 Nicotinic Acetylcholine Receptor.

Authors:  Tingting Chen; Conghui Wang; Sha Sha; Libin Zhou; Lei Chen; Ling Chen
Journal:  Mol Neurobiol       Date:  2015-07-22       Impact factor: 5.590

9.  Impaired geranylgeranyltransferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain.

Authors:  Sarah Afshordel; Wellington Gibson Wood; Urule Igbavboa; Walter E Muller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-02-07       Impact factor: 5.372

Review 10.  Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.

Authors:  Edith Hamel; Jessika Royea; Brice Ongali; Xin-Kang Tong
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.